*There is a concern that renin-angiotensin-aldosterone system (RAAS) blockers increase susceptibility to coronavirus 2019 (COVID-19).*There no evidence that treatment with RAAS blockers worsens the course of COVID-19.*Discontinuation of RAAS blockers may exacerbate cardiovascular comorbidities.*RAAS blockers should be continued in patients with otherwise stable conditions.